Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Myovant Sciences Ltd (NY: MYOV )

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Mar 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myovant Sciences Ltd

< Previous 1 2 3 4 5 Next >
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
From Myovant Sciences, Inc.
Via GlobeNewswire
CORRECTION -- Myovant Sciences, Inc.
From Myovant Sciences, Inc.
Via GlobeNewswire
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.
From Myovant Sciences, Inc.
Via GlobeNewswire
Why Is Myovant Sciences (MYOV) Stock Up 30% Today?
The prospect that shareholders could get 27% or more to tender their shares has MYOV stock up sharply today. 
Via InvestorPlace
Myovant Sciences Rejects Sumitovant/Sumitomo Pharma Buyout Offer Of $2.5B
Via Benzinga
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per... 
Via Benzinga
Nasdaq Jumps 270 Points; Silver Surges Over 8%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing around 270 points on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share. 
Via Benzinga
S&P 500 Surges 2%; Crude Oil Rises Sharply
U.S. stocks extended gains midway through trading, with the Dow Jones gaining more than 600 points on Monday. 
Via Benzinga
Blue Apron (APRN) Stock Falls 33% on CFO Departure, Stock Sale
Blue Apron (APRN) stock is sliding lower on Monday as investors react to its CFO leaving the company and plans for a stock sale. 
Via InvestorPlace
Myovant Sciences Rockets After Rejecting Lowball Sumitovant Biopharma Takeover Bid
Myovant shares rocketed to a year-high after turning down Sumitovant's offer. 
Via Investor's Business Daily
US Stocks Open Higher; Dow Jumps 250 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 250 points on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers LogicBio Therapeutics (NASDAQ:LOGC) shares moved upwards by 641.3% to $2.02 during Monday's pre-market session. The company's market cap stands at $66.5 million. 
Via Benzinga
Why Myovant Sciences Shares Are Skyrocketing Monday
Myovant Sciences Ltd (NYSE: MYOV) shares are trading higher by 30.85% to $23.50 during Monday's pre-market session after the company received an acquisition offer from Sumitovant Biopharma and... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning! 
Via InvestorPlace
Why Myovant Sciences Is Trading Higher By Over 26%; Here Are 31 Stocks Moving Premarket
Gainers Wearable Devices Ltd. (NASDAQ: WLDS) rose 58% to $1.39 in pre-market trading after declining around 8% on Friday. Wearable Devices, last week, posted a 1H loss of $0.18 per share. 
Via Benzinga
Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
From Myovant Sciences, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
  
Via Benzinga
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading. 
Via Benzinga
FDA Approves Myovant Sciences/Pfizer's Treatment For Endometriosis-Associated Pain
Via Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Myovant Sciences's Return On Invested Capital Insights
According to data from Benzinga Pro, during Q1, Myovant Sciences's (NYSE:MYOV) reported sales totaled $116.49 million. Despite a 64.17% increase in earnings, the company posted a loss of $21.24... 
Via Benzinga
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
Recap: Myovant Sciences Q1 Earnings
Myovant Sciences (NYSE:MYOV) reported its Q1 earnings results on Wednesday, July 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Myovant Sciences beat... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
From Myovant Sciences, Inc.
Via GlobeNewswire
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For July 27, 2022
Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report earnings for its second quarter. 
Via Benzinga
Earnings Outlook For Myovant Sciences
Myovant Sciences (NYSE:MYOV) is set to give its latest quarterly earnings report on Wednesday, 2022-07-27. Here's what investors need to know before the announcement. Analysts estimate that Myovant... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.